Source 1primary paper2026MED
Toolkit/Lysosome-targeting chimera
Lysosome-targeting chimera
Also known as: LYTAC, LYTACs
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
Lysosome-targeting chimeras (LYTACs), utilizing the endocytosis-lysosomal route, facilitate the selective degradation of secreted and transmembrane proteins.
Usefulness & Problems
No literature-backed usefulness or problem-fit explainer has been materialized for this record yet.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A composed arrangement of multiple parts that instantiates one or more mechanisms.
Techniques
Computational DesignTarget processes
degradationrecombinationInput: Chemical
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
LYTAC has shown promise in oncology, neurological conditions, and immune-mediated disorders.
It has exhibited promise in oncology, neurological conditions, and immune-mediated disorders.
LYTACs broaden the target spectrum of targeted protein degradation relative to intracellular-only approaches.
thereby considerably broadening the target spectrum of TPD
LYTAC faces challenges including intricate ligand design, potential immunogenicity, inadequate tissue selectivity, and restricted clinical validation.
Nevertheless, LYTAC encounters several obstacles, such as intricate ligand design, potential immunogenicity, inadequate tissue selectivity, and restricted clinical validation.
LYTACs use the endocytosis-lysosomal route to selectively degrade secreted and transmembrane proteins.
Lysosome-targeting chimeras (LYTACs), utilizing the endocytosis-lysosomal route, facilitate the selective degradation of secreted and transmembrane proteins
Since 2020, the LYTAC platform has expanded to include multiple lysosome-targeting receptor targeting techniques and delivery vehicles such as aptamers, peptides, and nanoparticles.
Since its inception in 2020, the LYTAC platform has consistently progressed, incorporating several Lysosome-targeting receptor (LTR) targeting techniques and innovative delivery vehicles, including aptamers, peptides, and nanoparticles.
Approval Evidence
1 source5 linked approval claimsfirst-pass slug lysosome-targeting-chimera
Lysosome-targeting chimeras (LYTACs), utilizing the endocytosis-lysosomal route, facilitate the selective degradation of secreted and transmembrane proteins.
Source:
application promisesupports
LYTAC has shown promise in oncology, neurological conditions, and immune-mediated disorders.
It has exhibited promise in oncology, neurological conditions, and immune-mediated disorders.
Source:
capabilitysupports
LYTACs broaden the target spectrum of targeted protein degradation relative to intracellular-only approaches.
thereby considerably broadening the target spectrum of TPD
Source:
limitationsupports
LYTAC faces challenges including intricate ligand design, potential immunogenicity, inadequate tissue selectivity, and restricted clinical validation.
Nevertheless, LYTAC encounters several obstacles, such as intricate ligand design, potential immunogenicity, inadequate tissue selectivity, and restricted clinical validation.
Source:
mechanism scopesupports
LYTACs use the endocytosis-lysosomal route to selectively degrade secreted and transmembrane proteins.
Lysosome-targeting chimeras (LYTACs), utilizing the endocytosis-lysosomal route, facilitate the selective degradation of secreted and transmembrane proteins
Source:
platform evolutionsupports
Since 2020, the LYTAC platform has expanded to include multiple lysosome-targeting receptor targeting techniques and delivery vehicles such as aptamers, peptides, and nanoparticles.
Since its inception in 2020, the LYTAC platform has consistently progressed, incorporating several Lysosome-targeting receptor (LTR) targeting techniques and innovative delivery vehicles, including aptamers, peptides, and nanoparticles.
Source:
Comparisons
No literature-backed comparison notes have been materialized for this record yet.
Ranked Citations
- 1.